Novaliq announced the European registration of NovaTears+Omega-3 for the enhanced treatment of the signs and symptoms of evaporative dry eye disease (DED).
Using Novaliq’s proprietary, water-free EyeSol drug delivery technology, NovaTears+Omega-3 is the first eye drop containing high concentrations of Omega-3 (0.2%) ethyl ester of plant origin. Previously unattainable, the treatment is available in a multidose bottle, demonstrating both superior stability at room temperature and the enabling properties of Novaliq’s water-free platform technology, according to a company news release.
NovaTears+Omega-3 stabilizes the lipid layer of the tear film and reduces the evaporation of the underlying water phase of the tear film and supplements the lipid layer with essential Omega-3 fatty acids. The outer layer of the natural tear film, the lipid layer, protects the tear film against evaporation. It contains a mixture of cholesterol, fatty acids, phospholipids and waxes. To stabilize the tear film in case of impairment and to reduce tear evaporation, the lipid layer can be supplemented by externally applied fatty acids. Ideally these fatty acids should be of natural origin and be present in the human body to minimize the risk of local intolerances.
NovaTears is the first, clinically proven lipid layer stabilizer that improves signs and symptoms in patients with DED without causing vision blurring. With the addition of Omega-3 fatty acid, this effect can be further enhanced. Until now Omega-3 fatty acids could only be reliably supplemented through diets (e.g. fish) or balanced nutrition.
“It is well-known that dry eye disease compromises the lipid layer of the tear film, which, in healthy eyes, protects the tear film against evaporation,” Jerry Cagle, PhD, Former Chief Scientific Officer of Alcon, and member of Novaliq’s Supervisory Board, said in a company news release. “The addition of Omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer. This will be a welcome and much-needed addition to ophthalmologists’ arsenal of DED products in Europe.”
“NovaTears as the first and only treatment specifically designed to treat evaporative DED provides high efficacy and great comfort to patients,” says Bernhard Günther, Founder and Chief Innovation Officer, Novaliq GmbH. “The therapeutic benefits of combining these qualities with those of Omega-3 fatty acids offer further advantages. I am confident that all dry eye patients will greatly benefit from this breakthrough innovation."